Format

Send to

Choose Destination
Ann Neurol. 2017 Jul;82(1):139-146. doi: 10.1002/ana.24980.

Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis.

Author information

1
Department of Neuroscience, Mayo Clinic, Jacksonville, FL.
2
Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL.
3
Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL.
4
Department of Neurology, University of Miami, Miami, FL.
5
Department of Neurology, Washington University School of Medicine, St Louis, MO.
6
Department of Neurology, University Hospital Mútua de Terrassa, and Research Foundation Mútua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain.
7
Centers for Networked Biomedical Research (CIBERNED), Madrid, Spain.
8
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
9
Department of Neurology and Penn Frontotemporal Degeneration Center, University of Pennsylvania, Philadelphia, PA.
10
Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA.
11
Department of Neurology, Emory University School of Medicine, Atlanta, GA.
12
Department of Neurology-Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.
13
Department of Pathophysiology and Transplantation, "Dino Ferrari" Centre, University of Milan, Milan, Italy.
14
Department of Pathology, Emory University School of Medicine, Atlanta, GA.
15
Motor Neuron Disorders Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.
16
Iron Horse Diagnostics, Scottsdale, AZ.
17
Department of Neurology, Mayo Clinic, Jacksonville, FL.

Abstract

As potential treatments for C9ORF72-associated amyotrophic lateral sclerosis (c9ALS) approach clinical trials, the identification of prognostic biomarkers for c9ALS becomes a priority. We show that levels of phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in c9ALS patients, and are largely stable over time. Moreover, c9ALS patients exhibit higher pNFH levels, more rapid disease progression, and shorter survival after disease onset than ALS patients without C9ORF72 expansions. These data support the use of CSF pNFH as a prognostic biomarker for clinical trials, which will increase the likelihood of successfully developing a treatment for c9ALS. Ann Neurol 2017;82:139-146.

PMID:
28628244
PMCID:
PMC5676468
DOI:
10.1002/ana.24980
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center